CTEC vs. HIK, HCM, SN, INDV, AMS, TSTL, BVC, SPEC, CNSL, and GNS
Should you be buying ConvaTec Group stock or one of its competitors? The main competitors of ConvaTec Group include Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Smith & Nephew (SN), Indivior (INDV), Advanced Medical Solutions Group (AMS), Tristel (TSTL), BATM Advanced Communications (BVC), INSPECS Group (SPEC), Cambridge Nutritional Sciences (CNSL), and Genus (GNS). These companies are all part of the "medical" sector.
ConvaTec Group (LON:CTEC) and Hikma Pharmaceuticals (LON:HIK) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.
In the previous week, Hikma Pharmaceuticals had 5 more articles in the media than ConvaTec Group. MarketBeat recorded 6 mentions for Hikma Pharmaceuticals and 1 mentions for ConvaTec Group. Hikma Pharmaceuticals' average media sentiment score of 0.47 beat ConvaTec Group's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the news media.
66.7% of ConvaTec Group shares are held by institutional investors. Comparatively, 38.8% of Hikma Pharmaceuticals shares are held by institutional investors. 20.2% of ConvaTec Group shares are held by insiders. Comparatively, 30.7% of Hikma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
ConvaTec Group pays an annual dividend of GBX 5 per share and has a dividend yield of 1.9%. Hikma Pharmaceuticals pays an annual dividend of GBX 57 per share and has a dividend yield of 2.9%. ConvaTec Group pays out 10,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Hikma Pharmaceuticals pays out 8,382.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Hikma Pharmaceuticals is clearly the better dividend stock, given its higher yield and lower payout ratio.
Hikma Pharmaceuticals has a net margin of 6.61% compared to ConvaTec Group's net margin of 6.08%. Hikma Pharmaceuticals' return on equity of 8.81% beat ConvaTec Group's return on equity.
ConvaTec Group currently has a consensus price target of GBX 307.17, suggesting a potential upside of 17.33%. Hikma Pharmaceuticals has a consensus price target of GBX 2,068.75, suggesting a potential upside of 4.43%. Given ConvaTec Group's stronger consensus rating and higher probable upside, equities research analysts clearly believe ConvaTec Group is more favorable than Hikma Pharmaceuticals.
ConvaTec Group has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.
Hikma Pharmaceuticals received 446 more outperform votes than ConvaTec Group when rated by MarketBeat users. Likewise, 70.56% of users gave Hikma Pharmaceuticals an outperform vote while only 66.54% of users gave ConvaTec Group an outperform vote.
Hikma Pharmaceuticals has higher revenue and earnings than ConvaTec Group. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than ConvaTec Group, indicating that it is currently the more affordable of the two stocks.
Summary
Hikma Pharmaceuticals beats ConvaTec Group on 13 of the 20 factors compared between the two stocks.
Get ConvaTec Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTEC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ConvaTec Group Competitors List
Related Companies and Tools
